Display options
Cite
Tanida S, Mizoshita T, Ozeki K, et al. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2014;7(2):118-21doi: 10.14740/jocmr1991w.
Tanida, S., Mizoshita, T., Ozeki, K., Tsukamoto, H., Mori, Y., Kubota, E., Kataoka, H., Kamiya, T., & Joh, T. (2015). The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. Journal of clinical medicine research, 7(2), 118-21. https://doi.org/10.14740/jocmr1991w
Tanida, Satoshi, et al. "The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis." Journal of clinical medicine research vol. 7,2 (2015): 118-21. doi: https://doi.org/10.14740/jocmr1991w
Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015 Feb;7(2):118-21. doi: 10.14740/jocmr1991w. Epub 2014 Nov 19. PMID: 25436030; PMCID: PMC4245064.
Copy Download .nbib Format: NLM
Share it on

J Clin Med Res. 2015 Feb;7(2):118-21. doi: 10.14740/jocmr1991w. Epub 2014 Nov 19.

The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis.

Journal of clinical medicine research

Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Hironobu Tsukamoto, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh

Affiliations

  1. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

PMID: 25436030 PMCID: PMC4245064 DOI: 10.14740/jocmr1991w

Abstract

A 43-year-old woman, diagnosed with ulcerative colitis (UC) at age of 30, received outpatient treatment with corticosteroids. However, flare-up occurred, and adalimumab (ADA) treatment commenced in July 2009. A complete remission with mucosal healing was achieved by 32 weeks after initiation of ADA therapy. Because of progressive skin eruptions, ADA maintenance was discontinued at 124 weeks. Regardless, complete remission with mucosal healing was maintained until 176 weeks. We concluded that ADA is an effective therapy to achieve a complete remission in a patient with steroid-refractory UC, and that long-term complete remission may be an important indication to discontinue biological therapy.

Keywords: Adalimumab; Biologic discontinuation; Complete remission; Refractory ulcerative colitis

References

  1. Gut. 2011 Jun;60(6):780-7 - PubMed
  2. Ann Rheum Dis. 2014 Mar;73(3):595-9 - PubMed
  3. N Engl J Med. 2005 Dec 8;353(23):2462-76 - PubMed
  4. Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31 - PubMed
  5. Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213 - PubMed
  6. Scand J Gastroenterol. 2013 Dec;48(12):1394-8 - PubMed
  7. World J Gastroenterol. 2014 Mar 21;20(11):2995-3001 - PubMed
  8. Gastroenterology. 2012 Feb;142(2):257-65.e1-3 - PubMed

Publication Types